5th Suna Kıraç Conference on Neurodegeneration Istanbul

5th Suna Kıraç Conference on Neurodegeneration Istanbul (ALS-IST 2019)

Selective Cellular Vulnerabilities in ALS and Relevant Therapeutic Modification of Gene Expression.”

November 7 - 9, 2019, Pera Museum
Conference Organizers : Robert H. Brown, Jr ., Jeffrey D. Macklis , A.Nazlı Başak


DRAFT PROGRAM, Sept. 04, 2019

THURSDAY, November 7, 2019, 7-9pm

Welcome Reception at the Pera Museum

FRIDAY, November 8, 2019

Welcome – A. Nazlı Başak              8:00-8:15am

Death and Dysfunction in Neurons: Programmed and Otherwise

Death in the Soma – Jungying Yuan * 8:15-9:00am
Axonal death 1 – Michael Coleman * 9:00-9:45am
Axonal death 2 – Aaron DiAntonio * 9:45-10:30am

Coffee Break 10:30-11:00

Axonal death 3 – Lukas Neukomm * 11:00-11:45am
Axonal death 4 – Alexandra Byrne * 11:45am-12:30pm
General Discussion 12:30-1:00pm

Lunch Break              1:00-1:45pm

Selective Cellular Vulnerability: Neurons and Otherwise - I

Overview of the genetics of MN death – A. Nazli Basak 1:45-2:30pm
The genetic architecture of the Turkish peninsula - Tayfun Özçelik   2:30-3:15pm
Type-specific subcellular vulnerability – Jeffrey Macklis     3:15-4:00pm

Coffee Break 4:00-4:30

Parkinson Disease – Greg Petsko * 4:30-5:15pm
Fronto-temporal Dementa – Bill Seeley * 5:15-6:00pm

General Discussion              6:00-6:45pm

CONFERENCE DINNER 8.00pm-
Venue TBA

SATURDAY, November 9, 2019

Selective Cellular Vulnerability: Neurons and Otherwise - II
TDP43 and MN death 1 (TDP43) - Jemeen Sreedharan       8:00-8:45am
C9orf72 and MNs: a new perspective - Ozgun Uyan   8:45-9:30am

Coffee Break 9:30-10:00

From single nuclei to systems – Daniel Jarosz *       10:00-10:45am
Microglia and stress granules – Daryl Bosco * 10:45-11:30am

Break: Group picture 11:30-11:45am

Therapeutic Modification of Gene Expression - I
SMA and ALS: therapeutic advances - Chris Henderson *   11:45am-12:30pm
ASO and other innovative ALS therapies – Don Cleveland *   12:30-1:15pm

Lunch Break     1:15-2:00pm

Therapeutic Modification of Gene Expression - II
ALS gene suppression: pilot studies - Bob Brown         2:00-2:45pm
New targets: Stathmin2 and beyond - Kevin Eggan *     2:45-3:30pm
General Discussion     3:30-4:00pm